Abionyx Financial Statements From 2010 to 2024

ABNX Stock  EUR 1.24  0.02  1.64%   
Abionyx Pharma financial statements provide useful quarterly and yearly information to potential Abionyx Pharma SA investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Abionyx Pharma financial statements helps investors assess Abionyx Pharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Abionyx Pharma's valuation are summarized below:
Abionyx Pharma SA does not presently have any fundamental signals for analysis.
Check Abionyx Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Abionyx Pharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . Abionyx financial statements analysis is a perfect complement when working with Abionyx Pharma Valuation or Volatility modules.
  
This module can also supplement various Abionyx Pharma Technical models . Check out the analysis of Abionyx Pharma Correlation against competitors.

Abionyx Pharma SA Company Current Valuation Analysis

Abionyx Pharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

 = 

Market Cap + Debt

-

Cash

More About Current Valuation | All Equity Analysis

Current Abionyx Pharma Current Valuation

    
  51.58 M  
Most of Abionyx Pharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Abionyx Pharma SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition

In accordance with the recently published financial statements, Abionyx Pharma SA has a Current Valuation of 51.58 M. This is 99.64% lower than that of the Healthcare sector and 98.89% lower than that of the Biotechnology industry. The current valuation for all France stocks is 99.69% higher than that of the company.

Abionyx Pharma SA Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Abionyx Pharma's current stock value. Our valuation model uses many indicators to compare Abionyx Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Abionyx Pharma competition to find correlations between indicators driving Abionyx Pharma's intrinsic value. More Info.
Abionyx Pharma SA is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Abionyx Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Abionyx Pharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

About Abionyx Pharma Financial Statements

Abionyx Pharma stakeholders use historical fundamental indicators, such as Abionyx Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Abionyx Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Abionyx Pharma's assets and liabilities are reflected in the revenues and expenses on Abionyx Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Abionyx Pharma SA. Please read more on our technical analysis and fundamental analysis pages.
ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein therapies for the treatment of cardiovascular and metabolic diseases. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France. ABIONYX PHARMA is traded on Paris Stock Exchange in France.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Abionyx Stock

Abionyx Pharma financial ratios help investors to determine whether Abionyx Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Abionyx with respect to the benefits of owning Abionyx Pharma security.